Plus   Neg

Stock Alert: Qualigen Therapeutics Jumps 60% In View Of COVID-19 Antibodies Test Sales

Shares of Qualigen Therapeutics, Inc. (QLGN) surged 60% on Wednesday morning after the company said it submitted an official notification to the FDA to commence sales in the U.S. of its COVID-19 antibodies test.

QLGN is currently trading at $6.36, up $2.38 or 60.08%, on the Nasdaq.

The company said the FastPack COVID-19 antibody test has already been submitted to the FDA for Emergency Use Authorization, but the notification enables Qualigen to commence sales even before the FDA considers or formally grants the EUA for the test.

Qualigen expects sales and shipments of the new test to begin in mid-July.

The FastPack COVID-19 antibody test is a chemiluminescent microparticle test intended for the qualitative detection of SARS-CoV-2 IgG antibodies in blood to identify individuals with an adaptive immune response to the virus that causes COVID-19, indicating recent or prior infection of the disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Transform SR Holding Management LLC is recalling about 19,900 units of 4-drawer chests, sold exclusively at Kmart stores, citing tip-over and entrapment risks for children, according to the U.S. Consumer Product Safety Commission. The recall involves chests with plastic drawer glides sold by Transform under the Essential Home brand. Amazon announced the extension of Project Zero, which protects and empowers brands to combat counterfeits, to seven new countries. The project is now available in Australia, Brazil, Netherlands, Saudi Arabia, Singapore, Turkey, and the UAE, along with ten other countries where Amazon has a store. Performance Food Group Co. (PFGC) reported Wednesday a net loss for the fourth quarter of $151.2 million or $1.19 per share, compared to net income of $63.2 million or $0.60 per share in the prior-year quarter. Excluding items, adjusted loss for the quarter was $0.86 per share, compared to adjusted...
Follow RTT